Core Viewpoint - Nocera Biopharma's stock price has shown a slight increase of 2.05% recently, but has experienced a decline over the past month, indicating potential volatility in the market [1]. Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [1]. Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%. However, the net profit attributable to shareholders was a loss of 64.41 million yuan, although this represents a 76.61% improvement compared to the previous period [2]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 16,500, marking an 8.66% rise. The average circulating shares per person remained unchanged at 0 [2]. - The top ten circulating shareholders include several new entrants, such as Wan Jia You Xuan and Ping An Medical Health, while some previous shareholders have exited the list [3].

Group 1 - The core viewpoint of the news is that Yipin Hong's stock price has shown a slight increase of 2.06% recently, but has experienced significant declines over the past 20 and 60 days, indicating volatility in its stock performance [1][2]. - As of January 5, Yipin Hong's stock price is reported at 34.24 yuan per share, with a total market capitalization of 15.466 billion yuan [1]. - The company has seen a net inflow of main funds amounting to 1.0571 million yuan, with large orders contributing significantly to the buying activity [1]. Group 2 - Yipin Hong's stock has decreased by 4.01% in the last five trading days, 28.96% over the last 20 days, and 39.17% over the last 60 days, indicating a downward trend in its stock performance [2]. - The company, established in 2002 and listed in 2017, focuses on the research, production, and sales of its own pharmaceuticals, with a revenue composition of 61.12% from children's medicine, 22.71% from chronic disease medicine, and 16.17% from other products [2]. - As of November 30, the number of shareholders has decreased to 20,400, while the average circulating shares per person have increased to 20,511 [2]. Group 3 - Yipin Hong has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed in the last three years [3]. - As of September 30, 2025, new institutional shareholders have entered the top ten circulating shareholders, including Hong Kong Central Clearing Limited and several mutual funds [3].

Core Viewpoint - The company, YuanDa Pharmaceutical, has made significant advancements in innovative products, showcasing its "self-research + introduction" strategy in the fields of nuclear medicine, traditional Chinese medicine for depression, and emergency treatments, indicating a strong potential for sustainable growth in the innovative drug sector [1][16]. Group 1: Innovative Product Developments - The company achieved success in its Phase II clinical trial for an innovative traditional Chinese medicine for depression [1]. - The FDA approved the company's self-researched FAP-targeted nuclear medicine for clinical research, while an introduced prostate cancer diagnostic nuclear medicine reached the end of its Phase III clinical trial in China, indicating imminent commercialization [1][2]. - The company launched the world's first epinephrine nasal spray for emergency treatment of type I allergic reactions in China, enhancing its cardiovascular emergency product line [1][14]. Group 2: Nuclear Medicine Advancements - The GPN01530 nuclear medicine, targeting FAP, has shown superior performance compared to current cancer diagnostic products, with a sensitivity of 80%-90% for certain cancers, potentially replacing the mainstream product 18F-FDG [2][3]. - TLX591-CDx, a prostate cancer diagnostic nuclear medicine, achieved a positive top-line result in its Phase III clinical trial, demonstrating a 100% positive predictive value for recurrent prostate cancer [4][5]. - The company has a robust pipeline with 16 innovative products in the registration phase, covering various radioactive isotopes and cancer types, indicating a comprehensive approach to nuclear medicine [7]. Group 3: Strategic Initiatives - The company employs a dual strategy of "self-research + global introduction," enhancing its innovation capabilities and product offerings in the nuclear medicine sector [6][10]. - The establishment of a comprehensive global industrial network, including R&D and production bases in Boston and Chengdu, supports the company's competitive edge in the nuclear medicine market [10][13]. - The company's proactive "China-US dual reporting" strategy accelerates drug approvals in major markets, enhancing the international market value of its products [10]. Group 4: Financial Performance and Market Outlook - The company reported a significant increase in revenue from innovative and barrier products, accounting for approximately 51% of total revenue, reflecting a year-on-year increase of 14.9 percentage points [16]. - The global nuclear medicine market is projected to grow from approximately $10.65 billion in 2023 to $31.44 billion by 2033, with a compound annual growth rate of about 11.45%, positioning the company to benefit from this market expansion [13]. - The company's market capitalization has doubled since the beginning of the year, indicating strong market recognition of its innovative strategy and growth potential [16].

Economic Data and Events - China will release December CPI and foreign exchange reserve data in the week of January 5 to January 11, 2026 [1] - The People's Bank of China will have a total of 13,236 billion yuan in reverse repos maturing [1] - The 16th China Internet Industry Annual Conference will be held in Beijing from January 7 to 8, 2026 [1] - The Eurozone will release December CPI and PMI data, while the US will publish the December non-farm payroll report [1] Stock Market Developments - Over 1,600 billion yuan in market value of restricted stocks will be unlocked this week, with 36 stocks involved, totaling over 4.3 billion shares [5][6] - Notable stocks include Baili Tianheng with a market value of 963.19 billion yuan, Guolian Minsheng at 180.08 billion yuan, and Jianshe Industrial at 168.95 billion yuan [6] New Stock Offerings - Two new stocks will be available for subscription: Zhixin Co., Ltd. on January 6 with a subscription limit of 180,000 shares at 21.88 yuan per share, and Kema Materials on the same day with a limit of 9,414,000 shares at 11.66 yuan per share [22][23] Policy and Regulatory Updates - The State Council has issued a comprehensive action plan for solid waste management, aiming for significant improvements by 2030, including a target of 4.5 billion tons of annual comprehensive utilization of solid waste [9] - The plan emphasizes a full-chain management approach across various sectors, including industrial and urban waste [9] Industry Insights - The low-altitude economy in Shanghai is projected to reach a core industry scale of around 80 billion yuan by 2028, with a complete industrial chain for new low-altitude aircraft [11][12] - The commercial aerospace sector is expected to see significant growth, with multiple new rocket launches planned and advancements in reusable rocket technology [13][19] Pharmaceutical Sector Developments - In 2025, China approved 76 innovative drugs, surpassing the previous year's total and achieving a record high, with over 1,300 billion USD in licensing transactions [14][15] - The focus for 2026 will be on next-generation ADCs, dual/multi-antibodies, small nucleic acids, and CAR-T therapies [15][16]

Group 1 - The year 2025 was a transformative period for fund investors, marked by a journey of cognitive upgrades and emotional adjustments, leading to a more rational and determined mindset as they approach 2026 [1] - The capital market in 2025 demonstrated resilience amidst volatility, with investors like Zhao maintaining high positions in technology and metals, while others like Li faced challenges due to emotional decision-making [2][3] - Investors are shifting from chasing trends to focusing on asset allocation and rational decision-making, recognizing the importance of discipline and risk management in navigating market complexities [5] Group 2 - Investors are planning to optimize their portfolio structures in 2026, with strategies such as increasing investments in index funds and concentrating on high-performing funds to enhance returns [4] - The experiences of investors in 2025 have led to a more pragmatic approach, emphasizing the need for a balanced allocation and a focus on quality assets to navigate potential market fluctuations [4][5] - The overall sentiment among investors is moving towards a long-term perspective, with an understanding that investment is a continuous journey that requires patience and respect for market dynamics [5]

市场也给不少"追风者"上了一课。罗女士曾试图通过"广撒网"的方式捕捉投资机会，持仓一度超过20只 基金，涵盖了人工智能、创新药等热门赛道。这种"基金超市"模式在普涨行情下收益可观，而当行情轮 动加快时，却陷入了顾此失彼的窘境。 李先生的经历则更具代表性。面对2025年的上涨，他起初因恐高而犹豫，却在市场情绪持续高涨时，在 阶段性高点重仓买入，随后承受了回调损失。他坦言，自己陷入了"越涨越不敢买，越不敢买越涨"的纠 结，结果在高位匆忙入场。此后，李先生并未频繁操作，面对账户的一片绿色，仍坚持自己的节奏。他 那句"宁可不动，也不要乱动"，不仅是对2025年的反思，也是对市场复杂性的深刻领悟。 沉淀与蜕变：优化配置结构 ● 本报记者 郝健 刚刚过去的2025年对于每一位基金投资者而言，不仅是基金净值的起伏曲线，更是一段认知升级、心态 博弈与自我和解的心路历程。从年初的谨慎试探，到年中的积极参与，再到年末的理性沉淀，一些基民 经历了资本市场的磨炼，逐渐摸索出适合自己的投资方法。面对已经开启的2026年，基民的心态少了一 分盲目，多了一分冷静与笃定。 迷雾与觉醒：复苏行情下的众生相 2025年的资本市场，在波动中展现韧 ...

要闻速递 外交部发言人就美国强行控制委内瑞拉总统马杜罗夫妇答记者问 4日，外交部发言人就美国强行控制委内瑞拉总统马杜罗夫妇答记者问。问：据报道，1月3 日，美国派兵强行控制委内瑞拉总统马杜罗夫妇并移送出境。多国政府发声对此表示反对。中 方对此有何评论？答：中方对美方强行控制马杜罗总统夫妇并移送出境表示严重关切，美方行 径明显违反国际法和国际关系基本准则，违反《联合国宪章》宗旨和原则。中方呼吁美方确保 马杜罗总统夫妇人身安全，立即释放马杜罗总统和夫人，停止颠覆委内瑞拉政权，通过对话谈 判解决问题。详情>> 韩国总统李在明抵达北京 开启就任后首次对华国事访问 4日下午，韩国总统李在明乘机抵达北京首都国际机场，开启为期4天的访华行程。此访是李在 明总统就任后首次访华，也是韩国总统时隔6年再次访华。 元旦假期海南离岛免税购物金额7.12亿元 据海口海关统计，元旦假期期间（2026年1月1日至3日），海口海关共监管离岛免税商品销售 44.2万件，同比增长52.4%；购物人数8.35万人次，同比增长60.6%；购物金额7.12亿元，同比 增长128.9%。 创新高！去年我国批准创新药76个 对外授权破千亿美元 据国家药监 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights that various segments within the pharmaceutical industry have seen multiple stocks with over 100% gains in 2025, particularly in the chemical preparation sector, which has outperformed due to the rise in valuations of innovative drugs and strong clinical data from pipelines [4][13] - The report anticipates continued opportunities in the innovative drug sector, driven by the global competitiveness of Chinese pharmaceutical companies and the recognition of their R&D capabilities by multinational corporations [5][14] - Emerging industries such as AI, brain-computer interfaces, and biomanufacturing are expected to gradually transform various segments of the pharmaceutical field, with ongoing efforts to identify investment opportunities within these areas [5][14] Summary by Sections 1. Performance of Pharmaceutical Segments - In 2025, the chemical preparation sector showed the best performance, with top stocks like Shuyou Shen, Guangsheng Tang, and Anglikang achieving over 100% gains due to favorable clinical data and valuation increases [4][13] - The bioproducts sector, including companies like Sanofi and Rongchang Biopharma, also saw significant gains driven by quality pipelines and business development opportunities abroad [4][13] - The pharmaceutical R&D outsourcing sector experienced a "Davis Double" effect, with companies like WuXi AppTec and Haoyuan Pharmaceutical reporting exceptional performance due to increased demand and exceeding expectations [4][13] 2. Market Trends and Weekly Performance - In the fifth week of December 2025, the pharmaceutical sector declined by 2.06%, underperforming the CSI 300 index by 1.47 percentage points, ranking 28th among 31 sub-industries [6][18] - The hospital sector had the smallest decline at 0.85%, while the offline pharmacy sector faced the largest drop at 4.11% [6][22] 3. Recommendations and Focus Areas - The report continues to recommend investment in the innovative drug sector and its supply chain, particularly in CXO and R&D services, as well as in emerging industries like AI and biomanufacturing [5][7][14] - Monthly and weekly stock recommendations include WuXi AppTec, Sanofi, and Haoyuan Pharmaceutical, among others, indicating a focus on companies with strong growth potential [7][15]

Group 1 - The core viewpoint of the news is that China Biologic Products Holdings (01177.HK) has seen significant insider buying from its executive director, demonstrating confidence in the company's long-term growth potential [1] - Executive Vice President Xie Xin purchased 1 million shares at an average price of HKD 6.4068 per share, totaling approximately HKD 6.4068 million, increasing his total holdings to 361 million shares, representing 1.92% of the company [1] - This marks Xie Xin's third purchase since July 2025, with previous acquisitions in July and August 2025 at average prices of HKD 6.47 and HKD 7.36 per share, respectively, indicating a total investment of over HKD 20 million in the past six months [1] Group 2 - The company announced that its innovative drug pipeline has achieved significant milestones since December last year, including the approval of the breast cancer drug Kemosil Capsules, the first global CDK2/4/6 inhibitor [2] - The oral GLP-1 receptor agonist TQF3250 for weight loss has received clinical application approvals from both the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) [2] - The TYK2/JAK1 inhibitor TQH3906 has shown positive progress in Phase II clinical trials for plaque psoriasis, and the ROCK2 inhibitor TDI01 has enrolled its first patient in a Phase III clinical trial for idiopathic pulmonary fibrosis, marking it as the first globally to enter this stage [2]

Core Viewpoint - Southbound capital is becoming a core force in reshaping the Hong Kong stock market, with a record net purchase of over HKD 1.4 trillion in 2025, marking a 73.89% increase from 2024 [1][3][11]. Group 1: Southbound Capital Trends - In 2025, the total net purchase of southbound capital reached HKD 14,048.44 billion, the highest in history, with cumulative net inflow exceeding HKD 51,000 billion since the launch of the Shanghai-Hong Kong Stock Connect [1][3]. - By the end of December, the market value of southbound capital holdings reached HKD 61,408.83 billion, accounting for over 12% of the total market capitalization of Hong Kong stocks [1][3]. - Throughout the year, there were 8 months where net purchases exceeded HKD 1,000 billion, with September recording the highest at HKD 1,885.18 billion [1][3]. Group 2: Key Stocks and Performance - In 2025, 137 stocks were active in southbound trading, with Alibaba-W leading in total trading volume at HKD 18,779.65 billion and a net purchase of HKD 1,778.69 billion [4][12]. - Alibaba-W saw a significant annual increase of 78.6%, the highest since its listing, while its revenue for Q3 2025 was reported at RMB 2,477.95 billion, a 5% year-on-year growth [4][12]. - Meituan-W experienced a decline of 31.91% in 2025, yet southbound capital continued to accumulate, with a net purchase of HKD 732.99 billion [5][13]. Group 3: Industry Insights - The top three industries by southbound capital holdings at the end of 2025 were Financials (HKD 15,703.51 billion), Information Technology (HKD 11,791.08 billion), and Consumer Discretionary (HKD 9,961.09 billion) [7][15]. - The Materials and Healthcare sectors saw the fastest growth in holdings, with increases of 238.92% and 125.51%, respectively, driven by rising global metal prices and the growing demand for innovative drugs [7][15]. - The innovative drug index in Hong Kong experienced a maximum increase of over 150% in 2025, supported by government measures to promote high-quality development in the sector [7][15].